Solana (NASDAQ:HSDT) Releases Earnings Results

Posted by Stanley Muller on May 17th, 2026

Solana (NASDAQ:HSDT – Get Free Report) announced its quarterly earnings data on Friday. The company reported ($1.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.96), FiscalAI reports. The firm had revenue of $3.62 million during the quarter, compared to the consensus estimate of $3.40 million. Solana had a negative return on equity of 104.96% and a negative net margin of 679.54%.

Here are the key takeaways from Solana’s conference call:

Solana Company said first-quarter revenue rose to $3.6 million from just $49,000 a year ago, driven mainly by $3.4 million of staking revenue. Management framed this as early validation of its digital asset treasury strategy.
The company reported a net loss of $99.8 million, largely due to non-cash markdowns tied to the roughly 33% decline in SOL during the quarter. It also recorded an $89.2 million unrealized loss on digital assets and receivables.
Management highlighted 6.9% average net staking yield in Q1, above the estimated system-wide average of about 6.0%. They said this outperformance came from validator selection, MEV capture, and active rebalancing.
The company completed an $8 million strategic equity raise in late April at a price described as about 1.1x NAV, and said part of the proceeds was used to buy SOL at attractive levels. Management called the raise immediately accretive to SOL per share.
Solana Company is expanding beyond treasury management into advisory services, validator infrastructure, and an AI-powered platform, with initial validator nodes expected to go live in late June. Management also said it completed the divestiture of its medical device business, which should help reduce future costs.

Solana Stock Down 3.8%

Solana stock traded down $0.09 during mid-day trading on Friday, hitting $2.30. 147,829 shares of the company were exchanged, compared to its average volume of 216,834. The company has a market capitalization of $126.25 million, a PE ratio of -0.02 and a beta of 1.06. The business has a fifty day moving average of $2.06 and a 200 day moving average of $2.92. Solana has a 1-year low of $1.59 and a 1-year high of $258.50.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on HSDT. Zacks Research upgraded shares of Solana to a “hold” rating in a research note on Monday, April 27th. Maxim Group assumed coverage on shares of Solana in a research report on Monday, April 6th. They set a “buy” rating and a $4.00 target price on the stock. B. Riley Financial started coverage on shares of Solana in a research report on Thursday, April 23rd. They issued a “buy” rating and a $3.00 price target for the company. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Solana in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $3.50.

Read Our Latest Analysis on Solana

Institutional Investors Weigh In On Solana

Hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC acquired a new position in Solana in the fourth quarter valued at about $1,006,000. LPL Financial LLC raised its stake in shares of Solana by 120.1% in the fourth quarter. LPL Financial LLC now owns 382,255 shares of the company’s stock valued at $1,105,000 after acquiring an additional 208,558 shares during the last quarter. State Street Corp bought a new position in shares of Solana in the fourth quarter valued at approximately $464,000. Cetera Investment Advisers acquired a new position in shares of Solana in the 4th quarter worth approximately $347,000. Finally, Marshall Wace LLP bought a new stake in Solana during the 4th quarter worth approximately $195,000. Institutional investors and hedge funds own 18.63% of the company’s stock.

Solana Company Profile

(Get Free Report)

Helius Medical Technologies, Inc (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.